Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785))
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Schneeweiss A (2022)
Publication Type: Journal article, Erratum
Publication year: 2022
Journal
Book Volume: 33
Pages Range: 743-744
Journal Issue: 7
DOI: 10.1016/j.annonc.2022.04.003
Abstract
The authors regret that in the original publication Fig. 3 was incorrectly presented. The correct figure is as below. The following corrections were made: - In figure 3A, part “additional TIL parameters”, box “iTILs postTx”: The number of patients was N=82 (not N=84 as published).- In figure 3B, row “Durvalumab-arm, sTILs preTx”, column “OR”: The estimated odds ratio was 1.29 (not 1.23 as published). This correction also affects the graphical representation left to column “OR”: The diamond marker must be in the center of the line.The authors would like to apologize for any inconvenience caused.[Formula presented]
Authors with CRIS profile
Involved external institutions
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
HELIOS Kliniken
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Centrum für Hämatologie und Onkologie Bethanien
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Medical Center Düsseldorf
Germany (DE)
Sana Kliniken AG
Germany (DE)
Praxis für Hämatologie und Onkologie Koblenz
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Freiburg
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Germany (DE)
HELIOS Kliniken
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Centrum für Hämatologie und Onkologie Bethanien
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Medical Center Düsseldorf
Germany (DE)
Sana Kliniken AG
Germany (DE)
Praxis für Hämatologie und Onkologie Koblenz
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Freiburg
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
How to cite
APA:
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.U.,... Schneeweiss, A. (2022). Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)). Annals of Oncology, 33(7), 743-744. https://doi.org/10.1016/j.annonc.2022.04.003
MLA:
Loibl, S., et al. "Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785))." Annals of Oncology 33.7 (2022): 743-744.
BibTeX: Download